Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Lymphomatoid Granulomatosis × varlilumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Plasmablastic Lymphoma 1 Lymphomatoid Granulomatosis 1 Lymphoma, Primary Effusion 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Glioblastoma 1 Burkitt Lymphoma 1

Interventions

varlilumab 1 Nivolumab 1 Immunoglobulin G 1 Disulfides 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03038672 2025-11-10

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting

54 enrolled 12 charts

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡